产品说明书

Etomoxir

Print
Chemical Structure| 124083-20-1 同义名 : (R)-(+)-Etomoxir
CAS号 : 124083-20-1
货号 : A482603
分子式 : C17H23ClO4
纯度 : 99%+
分子量 : 326.815
MDL号 : MFCD11227266
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(321.28 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Etomoxir irreversibly binds to the catalytic site of carnitine palmitoyltransferase-1 (CPT-1) on the outer mitochondrial membrane, inhibiting its activity and reducing fatty acid transport into mitochondria. Besides acting as a CPT-1 inhibitor, Etomoxir also functions as a peroxisomal proliferator in the liver, promoting DNA synthesis and liver growth, which suggests it might also act as a PPARalpha agonist[1]. As a member of the oxirane carboxylic acid group, Etomoxir is recognized for its potential as a therapeutic for heart failure. Acute treatment with Etomoxir irreversibly inhibits CPT-1, leading to reduced mitochondrial fatty acid β-oxidation, accumulation of cytosolic fatty acids, and enhanced glucose oxidation. Extended exposure (24 hours) to Etomoxir affects the expression of various metabolic enzymes, indicating diverse metabolic impacts[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.06mL

0.61mL

0.31mL

15.30mL

3.06mL

1.53mL

30.60mL

6.12mL

3.06mL
参考文献

[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36.

[2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44(2):415-23.

[3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.

[4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.